Fulcrum Therapeutics Target of Unusually Large Options Trading (NASDAQ:FULC)

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) was the target of unusually large options trading activity on Monday. Investors acquired 6,088 put options on the stock. This represents an increase of approximately 1,469% compared to the typical volume of 388 put options.

Insiders Place Their Bets

In other news, Director Alan Ezekowitz sold 18,000 shares of Fulcrum Therapeutics stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $3.65, for a total value of $65,700.00. Following the sale, the director owned 10,927 shares of the company’s stock, valued at $39,883.55. The trade was a 62.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of FULC. Mirae Asset Global Investments Co. Ltd. acquired a new position in Fulcrum Therapeutics in the 4th quarter valued at $30,000. Meeder Asset Management Inc. bought a new position in Fulcrum Therapeutics in the fourth quarter worth $39,000. Quarry LP bought a new position in Fulcrum Therapeutics during the third quarter worth about $35,000. Persistent Asset Partners Ltd acquired a new stake in Fulcrum Therapeutics in the 4th quarter valued at $75,000. Finally, Summit Securities Group LLC acquired a new stake in shares of Fulcrum Therapeutics in the 1st quarter valued at $53,000. 89.83% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Friday, July 17th. Cantor Fitzgerald cut Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 2nd. Wall Street Zen upgraded Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 2nd. HC Wainwright downgraded shares of Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and set a $3.00 target price for the company. in a research report on Tuesday, June 2nd. Finally, Truist Financial downgraded Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 price target for the company. in a report on Tuesday, June 2nd. One analyst has rated the stock with a Buy rating, seven have given a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Reduce” and an average price target of $8.20.

Fulcrum Therapeutics Stock Performance

Shares of NASDAQ FULC traded up $0.06 during trading on Monday, reaching $3.79. The stock had a trading volume of 3,298,162 shares, compared to its average volume of 1,625,234. The stock has a market cap of $289.56 million, a PE ratio of -3.14 and a beta of 3.05. Fulcrum Therapeutics has a one year low of $2.83 and a one year high of $15.74. The firm’s 50 day moving average price is $3.67 and its two-hundred day moving average price is $6.43.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings results on Thursday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10). On average, research analysts expect that Fulcrum Therapeutics will post -0.69 earnings per share for the current year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.